Curidium has attracted a scientific advisory board and has access to a broader team with a wealth of clinical, drug development and research expertise in the central nervous system area, bioinformatics, biostatistics, epidemiology and molecular genetics.

Dr Stewart Johnson
Dr. Stewart Johnson, Principal of the Pharmaceutical Consultancy, Safetymednet, is immediate past Chief Medical Officer, Ingenix Pharmaceutical Services. Dr. Johnson, who has qualifications in Medicine, Physiology and Pharmacology, was formerly Medical Director of Scherer DDS, prior to which he was Medical Director and Senior Vice-President, Clinical Research and Development at SmithKline Beecham Pharmaceuticals. Earlier he held UK medical directorships at Synthélabo and Wyeth and university appointments in Edinburgh and King’s College, London. He is Reader Emeritus in Pharmacology at the University of London.

Professor Paul Harrison
Professor Paul Harrison, Department of Psychiatry, University of Oxford, is a world-renowned expert in molecular neuropathology. He is a Clinical Reader in Psychiatry and a governing body fellow of Wolfson College, Oxford. Professor Harrison’s research interests are centred on the molecular neurobiology of psychiatric disorders. Professor Harrison has published more than 140 peer-reviewed research articles and reviews and is an advisor to several pharmaceutical companies. He is frequently invited to present at international scientific conferences.

Professor David Collier
Professor David Collier is Head of Molecular Genetics, Institute of Psychiatry, London. Professor Collier is a widely respected molecular geneticist who has, together with his research group, made significant contributions to the understanding of the genetic basis of psychiatric and neurological conditions. His research publications, exceeding more than 100 peer-reviewed research papers, are extensively cited by both professional scientific- as well as popular scientific communities. Professor Collier maintains research collaborations with a variety of pharmaceutical companies, such as GlaxoSmithKline, as well as several biotechnology firms.